Exploration of commercial cyclen-based chelators for mercury-197 m/g incorporation into theranostic radiopharmaceuticals.

ABSTRACT: A comprehensive investigation of the Hg²⁺ coordination chemistry and ^197m/gHg radiolabeling capabilities of cyclen-based commercial chelators, namely, DOTA and DOTAM (aka TCMC), along with their bifunctional counterparts, p-SCN-Bn-DOTA and p-SCN-Bn-TCMC, was conducted to assess the suitability of these frameworks as bifunctional chelators for the ^197m/gHg²⁺ theranostic pair. Radiolabeling studies revealed that TCMC and DOTA exhibited low radiochemical yields (0%-6%), even when subjected to harsh conditions (80°C) and high ligand concentrations (10^-4 M). In contrast, p-SCN-Bn-TCMC and p-SCN-Bn-DOTA demonstrated significantly higher ^197m/gHg radiochemical yields (100% ± 0.0% and 70.9% ± 1.1%, respec

SUBMITTER: Randhawa P 

PROVIDER: S-EPMC10881723 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature